Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Ipsen","sponsor":"University of Montreal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Enters into an Option Agreement with IRICoR and University of Montreal for A Discovery-stage Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ipsen"},{"company":"Sanofi","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, MD Anderson Join Forces to Ramp up Cancer R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sanofi"},{"company":"Pierre Fabre","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Pierre Fabre"},{"company":"Novadiscovery","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novadiscovery Expands Janssen Collaboration by Implementing its JINKO\u00ae Clinical Trial Simulation Platform for The Development of Lung Cancer Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Novadiscovery"},{"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Collaborates in The Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oncodesign"}]

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi, MD Anderson Join Forces to Ramp up Cancer R&D

Details:

The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 14, 2020

Sanofi Company Banner

18th Oligonucleotide Therapeutics

Not Confirmed

envelop

Contact Supplier

Oncodesign

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Servier Collaborates in The Treatment of Pancreatic Cancer

Details:

Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be responsible for clinical research activities. Servier will fund the associated research costs. The target identification program will be funded by OPM and Servier.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Servier

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 22, 2022

ASK
US

Upload
your Pipeline Activity

Novadiscovery

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novadiscovery Expands Janssen Collaboration by Implementing its JINKO® Clinical Trial Simulation Platform for The Development of Lung Cancer Models

Details:

The companies will now work together to use the JINKO® platform to add layers of biological complexity to the initial disease model and then run in silico trial simulations.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Janssen Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 16, 2021

ASK
US

Upload
your Pipeline Activity

Pierre Fabre

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre

Details:

Multi-target research collaboration leverages ImmunoPrecise’s powerful antibody discovery technologies with the long-standing expertise of Pierre Fabre in immuno-oncology.

Lead Product(s): Antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Talem Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 07, 2021

ASK
US

Upload
your Pipeline Activity

Ipsen

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ipsen Enters into an Option Agreement with IRICoR and University of Montreal for A Discovery-stage Oncology Program

Details:

University of Montreal/IRICoR will conduct and finance the research program until the license is exercised. Ipsen would assume all development activities and commercialize the drug candidate globally.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: University of Montreal

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 04, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY